← board
IMA
distress 3/10 · well-funded / low risk$5.970%today-67% from 52w high
Lead: moderate-to-severe atopic dermatitis · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$117M
Runway
2.1 yrs
Shares 1y
+1%
Price & events
-15.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-0.7%
1W
-0.3%
1M
-0.7%
3M
-15.6%
6M
-59.9%
1Y
-70.3%
2Y
-95.7%
5Y
-98.4%
All
Overview
- Market Cap
- $67.34M
- Volume
- 8.80K
- 52 Week Range
- $4.55 – $17.90
- Total Shares
- 11.28M
- Float Shares
- 5.80M
- Short %
- 3.64%
- % Held by Insiders
- 11.26%
- % Held by Institutions
- 48.16%
- RVOL
- 0.75x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- fourth quarter of 2026Guided 70%readoutPhase 2IMG-007 · Phase 2b topline readoutSEC 8-K
- July 1, 2025trial initiationsecondaryPhase 2IMG-007 · First patient dosed in global Phase 2b dose-finding study (ADAPTIVE Trial) in moderate-to-severe atopic dermatitis.SEC 8-K
- 2024-12-23partnershipIkena and Inmagene entered into a merger agreement to combine the companies.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-11WedbushUnderperform
- 2025-10-24Leerink PartnersOutperform
Competitors — moderate-to-severe atopic dermatitis
Recent news
- 2026-07-21ImageneBio principal accounting officer sells $17,334 in stock By Investing.com - Investing.com Nigeria
- 2026-07-21ImageneBio principal accounting officer sells $17,334 in stock - Investing.com
- 2026-07-21Form 4 ImageneBio Inc For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21Insider Sell: Robert Lally Sells Shares of ImageneBio Inc (IMA) - GuruFocus
- 2026-07-21Insider Sell: Robert Lally Sells Shares of ImageneBio Inc (IMA) - GuruFocus
- 2026-07-21ImageneBio Principal Accounting Officer Robert B. Lally sells USD 17,350 of common shares - Bitget
- 2026-07-20Insider Buyers Lose Additional US$9.8k As ImageneBio Dips To US$61m - simplywall.st
- 2026-07-19ImageneBio, Inc. Financial Disclosures & SEC Filings - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.